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While the world awaited the next influ-
enza pandemic to emerge from southern
China, “nature,” as always, caught us by
surprise. The unusual “atypical” pneu-
monia, subsequently called “severe acute
respiratory syndrome” (SARS), that
emerged out of southern China in late
2002 was not caused by influenza, but was,
in fact, caused by a novel coronavirus [1–
3]. Epidemiologically, infection with the
SARS coronavirus (SARS-CoV) is closely
linked with SARS [1, 4], and experimental
infection of cynomolgus macaques (Ma-
caca fascicularis) results in pathology rem-
iniscent of the human disease [4, 5]. Hu-
man coronaviruses 229E and OC43 are
known to be causes of the common cold
and have received scant attention, either
diagnostically or research wise, in the past
few decades. Coronaviruses also cause dis-
ease in animals that varies from trans-
missible gastroenteritis in pigs, to feline
infectious peritonitis in cats, to avian in-
fectious bronchitis in chickens. However,
phylogenetic relationships suggested that
this new virus was not closely related to
any of the previously known human or
animal coronaviruses and that SARS-CoV
may, in fact, be the first representative of
a new group within the coronavirus family
[6, 7]. The lack of serological evidence of
prior SARS-CoV infection in the healthy
population in many parts of the world,
including regions where the disease out-
breaks were the most severe, suggested
that this was a virus that had recently en-
tered the human population, presumably
from an animal reservoir [1, 8]. Although
the animal reservoir in nature remains to
be defined, the recent isolation of SARS-
CoV–like virus from small mammals in
live wild-game animal markets in south-
ern China confirmed the zoonotic origin
of the virus and suggested that these mar-
kets could potentially be the interface
where the inter-species jump from animals
to humans occurs [9].
SARS is an acute pneumonic illness and
is clinically difficult to distinguish from
other types of atypical pneumonia in the
absence of a clear epidemiological link to
other patients with the disease [1, 10, 11].
Because of the propensity for transmission
within hospitals, early diagnosis, isolation,
and management was critical, and labo-
ratory confirmation of the diagnosis early
in the course of illness was vital. SARS-
CoV infection is closely associated with
disease and has rarely been detected in the
absence of clinical disease. The question
is how best to detect infection early in the
course of the illness. Therein lies the
dilemma.
As with other microbial infections, the
options for diagnosis are the demonstra-
tion of the pathogen in clinical specimens
or the demonstration of a serological re-
sponse to the agent. Detection of sero-
conversion to SARS-CoV using immu-
nofluorescence and well-validated ELISA
tests has been a very reliable means for
confirming the diagnosis. However, the
antibody response appears only around
day 10 of the illness, and, in some patients,
it may take even longer [12]. Thus, se-
rological testing still remains the means for
retrospective diagnosis. To date, IgM or
other subtype assays have not been useful
for closing the diagnostic window within
the first week of illness, although future
research and development may improve
matters. Virus culture is still insensitive,
and, in any event, primary virus isolation
takes too long to be clinically relevant. Op-
tions such as shell vial culture may be con-
siderations in the future, when monoclo-
nal antibody reagents become available.
However, given the current recommen-
dation that culture of SARS-CoV be re-
stricted to biosafety level 3 containment,
culture-based diagnostic techniques are
unlikely to be widely available. Conven-
tional RT-PCR and recently established
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real-time PCR technologies have been re-
ported to detect this deadly virus in pa-
tients with SARS [1–3, 13–17].
These RT-PCR tests showed us that the
virus is detectable in specimens obtained
from the upper and lower respiratory
tracts, including nasopharyngeal aspirates
and throat swab specimens. Specimens
obtained from the lower respiratory tract,
including sputum samples [2], endotra-
cheal aspirates [8], and bronchial lavage
fluid, are excellent specimens for detection
of SARS-CoV. However, few patients ex-
pectorate sputum during the early stage of
the illness. Somewhat surprisingly, viral
RNA was also detected in feces and urine
samples, although urine was not the most
sensitive specimen at any stage of the ill-
ness [8]. The suitability of serum or pe-
ripheral blood leukocytes as a diagnostic
specimen remains to be examined. With
the first-generation RT-PCR tests, the
overall diagnostic yield in the second week
of illness was 180%, and feces specimens
yielded better results than did respiratory
specimens [8]. By use of quantitative as-
says, it was shown that the virus load in
the upper respiratory tract is low during
the first week of illness and peaks around
day 10 of illness [12]. Thus, in the first 5
days of illness, none of these specimens
gave a satisfactory diagnostic yield, and it
was clear that the low virus load at this
stage of illness posed a diagnostic chal-
lenge. This may be partly because the virus
targets the lower rather than the upper
respiratory tract [10, 11]. In any event,
when tests for diagnosis of SARS are com-
pared, it is important to characterize spec-
imens in relation to the duration of illness.
A number of approaches have been
taken to address the challenge. In this issue
of Clinical Infectious Diseases, Jiang et al.
[18] describe a real-time nested PCR
method for detection of SARS-CoV. With
their assay, cDNA obtained from a throat
swab sample was subjected sequentially to
2 rounds of amplification in a real-time
quantitative PCR platform. The test is able
to detect !10 copies of viral genome per
reaction. Although only a small number
of samples were evaluated, the assay seems
to be more sensitive than a commercial,
single-round RT-PCR kit. Discrepant re-
sults were all validated by serological test-
ing, which demonstrated the specificity of
their assay. The assay has a dynamic range
from at least 103 to 1 copies per reaction
and no detectable background signal from
negative control samples. More impor-
tantly, the turn-around time for this
method was much shorter than that for
the conventional nested RT-PCR assay.
However, the actual sensitivity and spec-
ificity of this method remains to be eval-
uated with a study involving a larger num-
ber of clinical specimens.
To develop a better diagnostic test for
SARS, we take an alternative approach.
For these reported assays, the target se-
quences are within the ORF1ab region.
Because of the presence of a large amount
of subgenomic viral mRNA in infected
cells, one would expect that the detection
rate of SARS-CoV might be increased by
targeting subgenomic viral mRNA [6, 7].
To explore this possibility, with some
colleagues, we recently compared the
amounts of genomic and subgenomic
RNA in clinical specimens [15]. To our
surprise, our results indicated that ge-
nomic viral RNA is the predominant viral
RNA species in clinical samples, suggest-
ing that there is no advantage in targeting
subgenomic mRNA sequences for clinical
diagnosis [15].
In another recent study [14], with some
colleagues, we demonstrated that improv-
ing specimen extraction alone can mark-
edly improve the sensitivity of the RT-PCR
assays and that, when the improved RNA
extraction protocol was combined with an
optimized and sensitive real time RT-PCR
assay, a sensitivity of 80% can be achieved
during the first 3 days of illness. A naso-
pharyngeal aspirate specimen (rather than
a throat swab specimen) must be used in
this assay for optimal results. Obtainment
of nasopharyngeal aspirates or nasopha-
ryngeal swab specimens from patients
with SARS has sometimes been a cause for
concern. However, with appropriate pre-
cautions, the procedures can be done
safely, and these specimens are the best
for the rapid diagnosis of infection with
alternative pathogens, such as influenza
virus, which are more likely to be the eti-
ological agent in many suspected out-
breaks of infection that are investigated
during this winter season. Recently, Tsang
et al. [16] demonstrated that positive RT-
PCR results for nasopharyngeal aspirate
samples were independent predictors of
mortality, implying that virus loads
might also be very useful for prognosis.
Thus, quantitative RT-PCR assays may
provide useful information for clinical
management.
It is not possible to predict whether
SARS will return. Given the likely exis-
tence of an animal reservoir, the reemerg-
ence of this disease remains possible. Its
reemergence anywhere in the world, es-
pecially if it occurs during the winter with
the cocirculation of influenza, will put in-
tense pressure on health care services and
diagnostic laboratories in many parts of
the world. Although one hopes that such
an eventuality will not arise, it is sensible
to be prepared to meet such a challenge.
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